Format

Send to

Choose Destination
Nat Med. 2014 Apr;20(4):415-8. doi: 10.1038/nm.3466. Epub 2014 Mar 9.

Plasma phospholipids identify antecedent memory impairment in older adults.

Author information

1
Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA.
2
1] Department of Oncology, Georgetown University Medical Center, Washington, DC, USA. [2] Department of Biochemistry, Georgetown University Medical Center, Washington, DC, USA.
3
1] Department of Neurology, Georgetown University Medical Center, Washington, DC, USA. [2] Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.
4
Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.
5
Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.
6
Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA.
7
1] Department of Public Health Sciences, University of Rochester School of Medicine, Rochester, New York, USA. [2].
8
Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York, USA.
9
Department of Medicine, Unity Health System, Rochester, New York, USA.
10
Department of Family Medicine, Unity Health System, Rochester, New York, USA.
11
Division of Long Term Care and Senior Services, Rochester General Hospital, Rochester, New York, USA.
12
1] Department of Neurobiology and Behavior, University of California, Irvine School of Medicine, Irvine, California, USA. [2].
13
Department of Neurobiology and Behavior, University of California, Irvine School of Medicine, Irvine, California, USA.

Abstract

Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no cures or disease-modifying therapies, and this may be due to our inability to detect the disease before it has progressed to produce evident memory loss and functional decline. Biomarkers of preclinical disease will be critical to the development of disease-modifying or even preventative therapies. Unfortunately, current biomarkers for early disease, including cerebrospinal fluid tau and amyloid-β levels, structural and functional magnetic resonance imaging and the recent use of brain amyloid imaging or inflammaging, are limited because they are either invasive, time-consuming or expensive. Blood-based biomarkers may be a more attractive option, but none can currently detect preclinical Alzheimer's disease with the required sensitivity and specificity. Herein, we describe our lipidomic approach to detecting preclinical Alzheimer's disease in a group of cognitively normal older adults. We discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a 2-3 year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.

PMID:
24608097
PMCID:
PMC5360460
DOI:
10.1038/nm.3466
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center